Company completes Phase 3 trial enrollment and attracts new U.S. investors
- Diamyd Medical achieves full enrollment in Phase 3 trial
- Company enters equity financing agreements
- Funding amounts to up to USD 125 million
Diamyd Medical has announced that it has completed the enrollment of participants in its Phase 3 clinical trial for a treatment targeting autoimmune diabetes. This significant development comes alongside the company's agreement with several new U.S. sector specialists for equity financing, amounting to as much as USD 125 million. The funding is expected to support the ongoing research and development of its diabetes treatment.
The equity financing agreements will facilitate advances in the company’s clinical pipeline, particularly as it moves forward with the Phase 3 trial. This trial is critical for evaluating the efficacy of Diamyd’s treatment in Type 1 diabetes patients. With full enrollment achieved, the company is now poised to analyze results and make progress in the field of diabetes management.
These investments demonstrate growing interest and confidence in Diamyd Medical's innovative approach to treating autoimmune diabetes. As the company capitalizes on this funding opportunity, it aims to contribute more significantly to advancements in diabetes care and patient outcomes.
